This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Lg Electronics Inc., Yonsei University. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 51,857 
1 out of 1,492 
Years Active: 2021
Title: Siyoung Song: Innovator in Cancer Diagnosis
Introduction
Siyoung Song is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer diagnosis through his innovative research and development.
Latest Patents
Siyoung Song holds a patent for a method for the discovery of a microRNA biomarker for cancer diagnosis. This invention relates to a novel miRNA biomarker specifically for the diagnosis of bile duct cancer or pancreatic cancer. The method involves diagnosing cancer by substituting the expression level of the miRNA biomarker into a novel SVM classifier function. This innovative approach enhances the accuracy of cancer diagnosis and provides a valuable tool for medical professionals.
Career Highlights
Throughout his career, Siyoung Song has worked with notable organizations, including LG Electronics Inc. and Yonsei University. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Siyoung Song has collaborated with esteemed colleagues such as Jaehoon Lee and Jungsu Lee. These partnerships have further enriched his research and development efforts in cancer diagnostics.
Conclusion
Siyoung Song's contributions to the field of cancer diagnosis through his innovative patent demonstrate his commitment to advancing medical technology. His work continues to impact the way cancer is diagnosed and treated, showcasing the importance of innovation in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile